You are here: Industry Insights > Amgen

News List

Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals? fiercepharma
July 30, 2018
Even though Amgen and Novartis rolled out their hot new migraine drug, Aimovig, at a lower-than-expected price of $6,900, the companies expected pushback from payers, and they prepared for that by handing out a lot of the product for free.
Amgen R&D head Harper to leave for new pastures fiercebiotech
July 30, 2018
Amgen’s head of R&D, Sean Harper, announced he is stepping down from the big biotech to pursue new opportunities in startups and early-stage companies.
Former major leaguers take the field for Amgen’s new multiple myeloma campaign fiercepharma
July 26, 2018
Retired All-Star major leaguers are busy again this summer pitching for Amgen’s multiple myeloma push.
EU expands scope of Amgen’s Xgeva pharmatimes
July 18, 2018
European regulators have expanded the treatment scope of Amgen’s Xgeva to include the prevention of skeletal-related events in adults with multiple myeloma.
Amgen, Novartis’ migraine therapy impresses again pharmatimes
July 16, 2018
Amgen and Novartis’ closely watched experimental migraine therapy Aimovig has impressed again in late stage trials, this time hitting targets in patients for which other preventative treatments failed to work or weren’t tolerated.
Amgen and Novartis present new data demonstrating long-term efficacy, safety and tolerability of Aimovig TM (erenumab-aooe) in patients with chronic and episodic migraine worldpharmanews
July 05, 2018
Amgen (NASDAQ:AMGN) today announced that the results of two open-label extension (OLE) studies of AimovigTM (erenumab-aooe) in patients with chronic and episodic migraine, respectively
Amgen, Novartis 'overwhelmed' by early interest in migraine drug Aimovig fiercepharma
July 04, 2018
Amgen and Novartis’ Aimovig, first in its new class of migraine meds, hit the scene in May. Patients were ready and waiting for it.
Amgen’s Blincyto gets full EU approval for rare leukaemia pharmatimes
June 21, 2018
European regulators have awarded Amgen’s Blincyto full approval for Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow thought to aff
Amgen/Novartis migraine med gets CHMP nod pharmafile
June 07, 2018
Amgen and Novartis have announced that their newly FDA-approved treatment for migraines has received a recommendation from the CHMP, generally a precursor to an approval by the EMA.
Mylan lands biosimilar sucker punch to Amgen’s blockbuster pharmafile
June 07, 2018
Mylan and Biocon have received FDA approval for their biosimilar to Amgen’s Neulasta (pegfilgrastim), setting the companies on track to snatch a chunk of the treatment’s $4.2 billion per year in sales, as recorded last year.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page